Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 70
Competitive European label for XultophyⓇ
Profile
•
XultophyⓇ is indicated for the treatment of adults with type 2 diabetes
in combination with oral glucose-lowering agents
XultophyⓇ is a fixed combination product consisting of insulin degludec and liraglutide having complementary
mechanisms of action to improve glycaemic control
Administered as dose steps: One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide
Efficacy
Convenience
Safety
.
On average HbA1c reduction of 1.9%¹ from baseline to end of trial confirmed to be superior against all comparators²
•
On average 2.7 kg weight loss from baseline in patients inadequately controlled on basal insulin
Once-daily administration at any time of the day, preferably at the same time of the day
The pre-filled pen can provide from 1 up to 50 dose steps in one injection
Lower rates of confirmed hypoglycaemia than with insulin degludec in patients on metformin +/- pioglitazone
Fewer experienced gastrointestinal side effects than patients treated with liraglutide
1 Source: DUALⓇ I (NN9068-3697), DUAL® II (NN9068-3912)
2 Insulin degludec, liraglutide and placebo
changing
diabetes®
novo nordiskView entire presentation